Maleat De Ergometrină Zentiva (Ergometrine Maleate)

Ergometrine maleate acts as a partial agonist at serotonin (5‑HT2), dopamine and alpha‑adrenergic receptors in the uterus. This multi‑receptor activity induces sustained uterine smooth‑muscle contraction and vasoconstriction, helping to compress uterine vessels and reduce bleeding.

The specific dose and administration schedule are determined by the prescribing clinician based on the patient’s condition, route of administration, and local clinical guidelines. Healthcare professionals should follow the product label and institutional protocols.

Ergometrine maleate is intended for use in the immediate postpartum period and is not administered during pregnancy. Safety data for breastfeeding are limited; clinicians should weigh potential benefits against risks and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Ergometrine maleate is an ergot‑derived uterotonic that provides potent, sustained uterine contraction, whereas oxytocin, a peptide hormone, offers a shorter‑acting effect. Ergometrine may be preferred when oxytocin alone is insufficient, but it carries a higher risk of hypertension and vasoconstrictive side effects.

The product should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. If temporary temperature excursions occur, follow the manufacturer’s guidance on product stability before use.

The injectable solution is given either intramuscularly or intravenously by a qualified healthcare professional. The route, injection site, and rate of administration are determined by the prescriber according to the clinical situation and institutional protocols.

Serious risks include severe hypertension, coronary artery spasm, pulmonary edema, thromboembolic events, and rare cases of ischemic necrosis of extremities. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after administration.

Ergometrine maleate is contraindicated in patients with uncontrolled hypertension, known hypersensitivity to ergot alkaloids, active coronary artery disease, or severe peripheral vascular disease. It should also be avoided in individuals receiving other potent vasoconstrictive agents unless clinically justified.